Related Experiment Video
Updated: Aug 15, 2026
10:30
A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Human type A botulism and treatment with 3,4-diaminopyridine
L E Davis1, J K Johnson, J M Bicknell
1Neurology Service, Department of Veterans Affairs Medical Center, Albuquerque, New Mexico.
Electromyography and Clinical Neurophysiology
|July 1, 1992
Summary
3,4-diaminopyridine did not improve muscle strength or respiratory function in a severe case of human botulism. Combining it with anti-cholinesterase medication offered no additional benefit, differing from some animal study findings.
Area of Science:
- Neurology
- Pharmacology
Background:
- Botulism is a rare but serious paralytic illness caused by toxins produced by Clostridium botulinum bacteria.
- 3,4-diaminopyridine (3,4-DAP) has shown potential in animal models for treating botulinum toxin poisoning by enhancing neuromuscular transmission.
Observation:
- This study investigated the efficacy of 3,4-diaminopyridine in a human patient with severe food-borne type A botulism.
- The patient exhibited significant impairment in muscle strength, respiratory function, and electromyographic compound muscle action potentials.
Findings:
- Despite treatment with 3,4-diaminopyridine in a double-blind, placebo-controlled setting, no improvement was observed in the patient's muscle strength, respiratory function, or electrophysiological parameters.
- The addition of an anti-cholinesterase medication to 3,4-diaminopyridine did not yield any discernible clinical benefit.
Implications:
- The findings suggest that 3,4-diaminopyridine may not be effective for treating severe human botulism, contrasting with some preclinical data.
- Further research is needed to understand the discrepancies between animal models and human responses to 3,4-diaminopyridine in botulism treatment.
Related Concept Videos
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Tetanus
Tetanus is a life-threatening neurological disorder characterized by persistent muscle contractions and spastic paralysis. It is caused by Clostridium tetani, a motile, Gram-positive, rod-shaped, obligate anaerobe. These bacteria produce terminal endospores, giving them a distinctive “lollipop” or “tennis-racket” appearance. They thrive in anaerobic environments, such as those found in deep puncture wounds.Once introduced into the body, the spores germinate into vegetative cells. These cells...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...